22 unchanged sentences
NASDAQ Composite Index 100.00 101.37 103.99 110.87 119.09 98.49 115.04 119.50 119.71 134.63 115.84 151.69 168.74 195.11
−Removed: 100.00 101.37 103.99 110.87 119.09 98.49 115.04 119.50 119.71 134.63
NASDAQ Biotechnology Index 100.00 102.71 102.77 105.93 117.79 93.61 108.16 105.72 96.61 117.11 105.08 133.35 132.25 148.06
−Removed: 100.00 102.71 102.77 105.93 117.79 93.61 108.16 105.72 96.61 117.11
Recent Sales of Unregistered Securities
−Removed: There were no sales of unregistered securities during the period covered by this Annual Report on Form 10-K, other than those previously reported in a Quarterly Report on Form 10-Q or in a Current Report on Form 8-K.
+Added: On September 22, 2020, we issued and sold 13,310,243 shares of our common stock to Biogen for an aggregate purchase price of $465.0 million pursuant to the terms of a common stock purchase agreement with BIMA and in connection with the Biogen Collaboration Agreement.
+Added: No underwriters were involved in the sale and the book entry position representing the securities sold and issued contain legends restricting transfer of the securities without registration under the Securities Act or an applicable exemption from registration.
+Added: The offer, sale and issuance of the securities described above was exempt from registration under the Securities Act under Section 4(a)(2) of the Securities Act as a transaction by an issuer not involving a public offering.
+Added: The recipient of securities in this transaction acquired the securities for investment only and not with a view to or for sale in connection with any distribution thereof and appropriate legends were affixed to the securities issued in this transaction.
+Added: The recipient of securities in this transaction was an accredited person and had adequate access, through employment, business or other relationships, to information about the registrant.
Use of Proceeds from Registered Securities
17 unchanged sentences
Not applicable.
−Removed: SELECTED FINANCIAL DATA
−Removed: The following tables summarize our selected consolidated financial data for the periods and as of the dates indicated.
−Removed: We derived the consolidated financial data for the years ended December 31, 2019, 2018, and 2017 and as of December 31, 2019 and 2018 from our audited consolidated financial statements and related notes included elsewhere in this report.
−Removed: We derived the consolidated financial data for the years ended December 31, 2016 and 2015 and as of December 31, 2017, 2016 and 2015 from our audited consolidated financial statements that are not included elsewhere in this report.
−Removed: Our historical results are not necessarily indicative of the results that may be expected in the future.
−Removed: You should read the consolidated financial and other data below in conjunction with the section titled “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and our consolidated financial statements and related notes included elsewhere in this report.
−Removed: Year Ended December 31,
−Removed: 2019 2018 2017 2016 2015
−Removed: (In thousands, except share and per share amounts)
−Removed: Consolidated Statements of Operations and Comprehensive Loss Data:
−Removed: Collaboration revenue $ 26,678 $ 129,160 $ — $ — $ —
−Removed: Operating expenses:
−Removed: Research and development 193,382 143,183 74,460 75,702 11,571
−Removed: General and administrative 46,480 32,349 15,680 11,731 5,108
−Removed: Total operating expenses 239,862 175,532 90,140 87,433 16,679
−Removed: Loss from operations (213,184) (46,372) (90,140) (87,433) (16,679)
−Removed: Interest and other income (expense), net 15,219 10,132 1,955 781 (109)
−Removed: Loss before income taxes (197,965) (36,240) (88,185) (86,652) (16,788)
−Removed: Income tax benefit 351 — — — —
−Removed: Net loss (197,614) (36,240) (88,185) (86,652) (16,788)
−Removed: Other comprehensive income (loss):
−Removed: 999 (281) 5 (373) —
−Removed: Comprehensive loss $ (196,615) $ (36,521) $ (88,180) $ (87,025) $ (16,788)
−Removed: Net loss per share, basic and diluted
−Removed: $ (2.07) $ (0.39) $ (5.89) $ (13.49) $ (5.58)
−Removed: Weighted average number of shares outstanding, basic and diluted
−Removed: 95,608,208 92,621,991 14,964,144 6,424,720 3,006,379
−Removed: As of December 31,
−Removed: 2019 2018 2017 2016 2015
−Removed: Consolidated Balance Sheet Data:
−Removed: Cash, cash equivalents and marketable securities
−Removed: $ 455,242 $ 612,178 $ 466,976 $ 250,911 $ 30,740
−Removed: Working capital (1)
−Removed: 384,687 448,050 395,443 172,849 29,950
−Removed: Total assets 553,231 661,984 486,721 271,067 36,683
−Removed: Total liabilities 158,341 115,139 20,925 16,548 4,009
−Removed: Convertible preferred stock — — — 348,673 48,308
−Removed: Accumulated deficit (425,551) (227,937) (191,697) (103,512) (16,860)
−Removed: Total stockholders' equity (deficit) $ 394,890 $ 546,845 $ 465,796 $ (94,154) $ (15,634)
−Removed: __________________________________________________
−Removed: (1) We define working capital as current assets less current liabilities.
−Removed: See our consolidated financial statements for further details regarding our current assets and current liabilities.
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.